<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Granulocyte colony-stimulating factor has had a major impact on the management of severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo>--a collective term referring to congenital, idiopathic, or cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> patients respond to G-CSF with increased neutrophils, reduced <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, and improved survival </plain></SENT>
<SENT sid="2" pm="."><plain>Some responders with <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> (termed <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann's syndrome</z:e> herein) and <z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> have developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, which raises the question of the role of G-CSF in pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>The issue is complicated because both disorders have a propensity for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> as part of their natural history </plain></SENT>
<SENT sid="4" pm="."><plain>OBJECTIVE AND METHODS: To address this, the Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> International Registry used its large database of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> patients treated with G-CSF to determine the incidence of malignant myeloid transformation in the two disorders, and its relationship to treatment and to other patient characteristics </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: As of January 2001, of the 383 patients with congenital forms of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in the Registry, 48 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (crude rate, about 12.5%) </plain></SENT>
<SENT sid="6" pm="."><plain>No statistically significant relationships were found between age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and patient gender, G-CSF dose, or duration of G-CSF therapy </plain></SENT>
<SENT sid="7" pm="."><plain>What was observed, however, was the multistep acquisition of aberrant cellular genetic changes in marrow cells from <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann's syndrome</z:e> patients who transformed, including activating ras oncogene mutations, clonal cytogenetic abnormalities, and G-CSF receptor mutations </plain></SENT>
<SENT sid="8" pm="."><plain>The latter in murine models produces a hyperproliferative response to G-CSF, confers resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and enhances cell survival </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Since <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann's syndrome</z:e> and <z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> are inherited forms of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, G-CSF may accelerate the propensity for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in the genetically altered stem and progenitor cells, especially in those with G-CSF receptor and ras mutations (82% and 50% of <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann's syndrome</z:e> patients who transform, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Alternatively, and equally plausible, G-CSF may simply be an innocent bystander that corrects <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, prolongs patient survival, and allows time for the malignant predisposition to declare itself </plain></SENT>
<SENT sid="11" pm="."><plain>Only careful long-term follow-up of the cohort of patients receiving G-CSF will provide the answer </plain></SENT>
</text></document>